UBS Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price
Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by equities research analysts at UBS Group from $315.00 to $319.00 in a report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. UBS Group’s price target indicates a potential upside of 8.03% from the company’s […]
Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by equities research analysts at UBS Group from $315.00 to $319.00 in a report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. UBS Group’s price target indicates a potential upside of 8.03% from the company’s […]